DNA fusion vaccines enter the clinic
Stevenson, Freda K., Mander, Ann, Chudley, Lindsey and Ottensmeier, Christian H. (2011) DNA fusion vaccines enter the clinic. Cancer Immunology Immunotherapy, 60, (8), 1147-1151. (doi:10.1007/s00262-011-1042-2). (PMID:21644035).
Full text not available from this repository.
Induction of effective immune attack on cancer cells in patients requires conversion of weak tumor antigens into strong immunogens. Our strategy employs genetic technology to create DNA vaccines containing tumor antigen sequences fused to microbial genes. The fused microbial protein engages local CD4+ T cells to provide help for anti-tumor immunity, and to reverse potential regulation. In this review, we focus on induction of CD8+ T cells able to kill target tumor cells. The DNA vaccines incorporate tumor-derived peptide sequences fused to an engineered domain of tetanus toxin. In multiple models, this design induces strong CD8+ T-cell responses, able to suppress tumor growth. For clinical relevance, we have used "humanized" mice expressing HLA-A2, successfully inducing cytolytic T-cell responses against a range of candidate human peptides. To overcome physical restriction in translating to patients, we have used electroporation. Clinical trials of patients with cancer are showing induction of responses, with preliminary indications of suppression of tumor growth and evidence for clinically manageable concomitant autoimmunity.
|Subjects:||Q Science > QH Natural history > QH426 Genetics
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
|Divisions:||Faculty of Medicine > Cancer Sciences
|Date Deposited:||19 Apr 2012 14:11|
|Last Modified:||26 Apr 2013 05:42|
|Contributors:||Stevenson, Freda K. (Author)
Mander, Ann (Author)
Chudley, Lindsey (Author)
Ottensmeier, Christian H. (Author)
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)